Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

The SWOG 1608 and Phase Ib/II Trials for Follicular Lymphoma

July 9th 2019

The GADOLIN and GALEN Trials for Follicular Lymphoma

July 9th 2019

Second-Line Treatment for Follicular Lymphoma

July 9th 2019

Untreated Follicular Lymphoma and the Role of MRD Testing

July 9th 2019

Frontline Treatment for Follicular Lymphoma

July 9th 2019

Risk Stratification in Follicular Lymphoma

July 9th 2019

Treating Follicular Lymphoma: Addressing Unmet Needs

July 9th 2019

Treating Relapsed/Refractory Follicular Lymphoma

July 9th 2019

Obinutuzumab Versus Rituximab in Frontline FL

July 9th 2019

FL: Interpreting and Applying GALLIUM Data in Practice

July 9th 2019

The GALLIUM Study in Follicular Lymphoma

July 9th 2019

The National LymphoCare Study in Follicular Lymphoma

July 9th 2019

Frontline Treatment Regimens in Follicular Lymphoma

July 9th 2019

Initiating Therapy in Follicular Lymphoma

July 9th 2019

Risk Assessment for Patients With Follicular Lymphoma

July 9th 2019

Optimal Strategies to Help Diagnose Follicular Lymphoma

July 9th 2019

Retesting for FLT3 Mutation Status in AML

July 9th 2019

Jordan Clark, the chief commercial officer at Diaceutics, discusses FLT3 retesting in a relapsed acute myeloid leukemia setting.

Treatment of Hairy Cell Leukemia: Overview and First-Line Options

July 8th 2019

Hairy cell leukemia is a rare malignancy for which treatment has progressed significantly in recent years.

New Agents Abound in Benign Hematologic Disorders

July 8th 2019

Kleber Yotsumoto Fertrin, MD, PhD, provided insight into the new options that have emerged in the treatment landscape of benign hematologic malignancies.

Therapeutic Developments in AML Lead to Sequencing Questions

July 3rd 2019

Robert L. Redner, MD, highlights some of the newer available agents in acute myeloid leukemia and ongoing studies that could impact clinical practice.